Lyell Immunopharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Lyell Immunopharma sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Lyell Immunopharma: 6 sponsored US clinical trials, 3 recruiting.
Lyell Immunopharma sponsors 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Hodgkin Lymphoma, with 2 trials.
Upper-quartile sponsor footprint
Lyell Immunopharma sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558
Study of LYL314 in Aggressive Large B-Cell Lymphoma
NCT05826535
GCC19CART for Patients With Metastatic Colorectal Cancer
NCT05319314
A Biomarker Screening Protocol for Participants With Solid Tumors
NCT05891197
A Study to Investigate LYL845 in Adults With Solid Tumors
NCT05573035
A Study to Investigate LYL797 in Adults With Solid Tumors
NCT05274451
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Lyell Immunopharma pipeline
3 recruiting of 6 indexed (50% open).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Non-Hodgkin Lymphoma (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lyell Immunopharma: open-pipeline peers nationwide
Peers matched on 6 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Lyell Immunopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Lyell Immunopharma page
6 registered trials is a research-attention snapshot, not an endorsement of Lyell Immunopharma or any single study.
- 3 of Lyell Immunopharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Hodgkin Lymphoma is the condition Lyell Immunopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Hodgkin Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Lyell Immunopharma pipeline card: 6 registered trials from official public datasets.Report a data error.